ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Antibody-Empowered Nanomedicine for Precise Biomedical Applications.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The advancement of nanotechnology has positioned nanomedicine as powerful tools for disease diagnosis and treatment. However, the clinical efficacy of conventional nanomedicine is often limited by its passive targeting strategies and limited range of therapeutic mechanisms, leading to suboptimal accumulation at diseased sites and compromised therapeutic outcomes. Fortunately, the incorporation of antibodies, with their unparalleled targeting specificity and immune-activating capabilities, presents a pivotal strategy to overcome these hurdles of nanoparticles. This review systematically summarizes the current progress in antibody-empowered nanomedicine. Different antibody functionalization strategies for nanoparticles, along with their respective advantages, limitations, and typical applications, are first discussed. This review then individually describes the classification of these nanomedicines based on antibody structures, such as IgG-like antibodies, antibody fragments, and novel antibody-nanomedicine fusion formats. Subsequently, a specific emphasis is placed on the highlight of their biomedical applications in diagnostics, bioimaging, and the treatment of various diseases. Finally, ongoing challenges and prospects in the clinical translation of antibody-empowered nanomedicine are critically examined. This review is intended to catalyze interdisciplinary breakthroughs that propel antibody-empowered nanomedicine as an important pillar of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.